NVCR News and Press, NovoCure Limited From 10/29/20

Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020 Quarterly net income of $9.3 million with $0.09 in earnings per share Novocure (NASDAQ: NVCR) today reported fi...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q3 earnings results on Wednesday, October 28th, after market close.The consensus EPS Estimate is $0.04 (+100.0% Y/Y) and the consensus Revenue Estimate is $120.02M (+30.3% Y/Y).Over the last 1 year, NVCR has beaten EPS estimates 25% of the time ...

Shares of NovoCure have doubled since July '20. The recent gains seem to have been inspired by the company teaming up with pharmaceutical giant, Merck, in first-line NSCLC, and growing acceptance in the medical community. Furthermore, many catalysts are on the horizon in 2021 and ...

As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...

Valuations for stocks such as Datadog (DDOG), DraftKings (DKNG), NovoCure (NVCR), and Chegg (CHGG) look stretched. The company's current and expected financials fail to justify their valuations. Its best to avoid these stocks for the remainder of this year. The S&P 500 has gained appr...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the t...

Novocure’s virtual Research & Development Day on November 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research &am...

Unfortunately, glioblastoma is an aggressive brain tumor that still remains difficult to treat. To this day, there is still an unmet need for treatment, with only 8.7% of patients surviving for up to two years, according to Tactical Therapeutics. However, it appears some companies are making ...

In a year dominated by the Covid crisis and the search for a treatment/vaccine, the last week has seen progress in the fight against cancer, and helped send the biotech sector surging. More news on: Gilead Sciences, Inc., Merck & Co., Inc., Immunomedics, Inc., , News on ETFs Read mo...

Novocure (NASDAQ: NVCR) announced today that William Doyle, the company’s Executive Chairman, and Dr. Uri Weinberg, the company’s Chief Science Officer, will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020. Mr. Doyle and Dr. Weinberg will t...